News
Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable
27 Mar 24
News
Ipsen's Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA
13 Feb 24
Biotech, News, FDA, General
FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma
13 Feb 24
Biotech, News, General
Press releases
Merrimack Receives $225 Million Milestone Payment from Ipsen
27 Mar 24
Press Releases
Merrimack Reports Full Year 2023 Financial Results
7 Mar 24
Press Releases
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
13 Feb 24
Press Releases